"Now, BJP MPs Take Two Steps Back On Seeing Me," Says Rahul Gandhi

Washington, Feb 22: US President Donald Trump will raise the issue of religious freedom with Prime Minister Narendra Modi during his visit to India next week, the White House said on Friday, noting that the US has great respect for India's democratic traditions and institutions.

"President Trump will talk about our shared tradition of democracy and religious freedom both in his public remarks and then certainly in private. He will raise these issues, particularly the religious freedom issue, which is extremely important to this administration," a senior official told reporters in a conference call.

The official was responding to a question on whether the president was planning to speak to Modi on the Citizenship (Amendment) Act or the National Register of Citizens.

"We do have this shared commitment to upholding our universal values, the rule of law. We have great respect for India's democratic traditions and institutions, and we will continue to encourage India to uphold those traditions," the official said, requesting anonymity.

"And we are concerned with some of the issues that you have raised," the senior administration official said, in response to the question on CAA and NRC.

"I think the President will talk about these issues in his meetings with Prime Minister Modi and note that the world is looking to India to continue to uphold its democratic traditions, respect for religious minorities," the official said.

"Of course, it's in the Indian constitution -- religious freedom, respect for religious minorities, and equal treatment of all religions. So this is something that is important to the president and I'm sure it will come up," said the official.

Pointing out that India has a strong democratic foundation, the official said India is a country rich in religious, linguistic, and cultural diversity.

"In fact, it's the birthplace of four major world religions," the official noted.

New Delhi, Jun 9: BJP leader Jyotiraditya Scindia and his mother Madhavi Raje Scindia have tested positive for COVID-19 and are currently undergoing treatment in a Delhi hospital, India Today reported on Tuesday.

They were admitted on Monday to Max Super Specialty Hospital, Saket, after the two complained of throat irritation and fever.

"Not so good news: @JM_Scindia and his mother have tested positive for corona, The former Cong turned BJP leader from MP has been admitted to hospital.. Wish him a speedy recovery!" tweeted Rajdeep Sardesai, consulting editor at the India Today group.

Breaking now: Not so good news: @JM_Scindia and his mother have tested positive for corona, The former Cong turned BJP leader from MP has been admitted to hospital.. Wish him a speedy recovery!  @IndiaToday

— Rajdeep Sardesai (@sardesairajdeep) June 9, 2020

Scindia, former Congress MP from Guna constituency in Madhya Pradesh, quit the party and joined BJP last March. Scindia, who was once Minister of State with independent charge for Power, is the BJP candidate for the upcoming Rajya Sabha elections from Madhya Pradesh.

Bengaluru, Apr 30: Shares of Glenmark Pharmaceuticals Ltd rose almost 9% on Thursday after the Indian drugmaker got an approval to conduct clinical trials with antiviral drug favipiravir, seen as a potential treatment for COVID-19.

Favipiravir, manufactured under the brand name Avigan by a unit of Japan's Fujifilm Holdings Corp and approved for use as an anti-flu drug in the Asian island country in 2014, has been effective, with no obvious side-effects, in helping coronavirus patients recover, a Chinese official told reporters at a news conference last month.

"After having successfully developed the API and the formulations ... Glenmark is all geared to immediately begin clinical trials on favipiravir on COVID-19 patients in India," Sushrut Kulkarni, executive vice-president for Global R&D, Glenmark Pharmaceuticals, said in a statement. 

The Drug Controller General of India, the country's drug regulator, did not immediately respond to Reuters request for comment.

On Wednesday, another Indian pharmaceutical company, Strides Pharma Science Ltd, said it had developed and commercialized favipiravir antiviral tablets, and had applied to Indian drug authorities to start trials.

Shares of Mumbai-based Glenmark Pharmaceuticals, which rose as much as 8.9% to 359 rupees ($4.78), was trading up 5.9%, as of 0407 GMT.